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ABSTRACT  20 
Background 21 
Taxanes are mitotic poisons widely used in the treatment of non-small cell lung cancer 22 
(NSCLC), however, little is known about potential molecular modulators of response to these 23 
compounds.  Aurora B (AURKB) is a critical regulator of the mitotic spindle assembly, 24 
previously shown overexpressed in NSCLC. Here, we investigated the hypothesis that AURKB 25 
expression modulates the efficacy of taxanes in NSCLC cells.  26 
Methods 27 
AURKB mRNA expression was determined by qPCR in 132 frozen NSCLC tissues and 9 NSCLC 28 
cell lines. AURKB expression was knocked down in cell lines using multiple shRNA constructs. 29 
Barasertib was used to specifically inhibit Aurora B activity, determined by the level of H3S10 30 
phosphorylation. 31 
Results  32 
Frequent AURKB mRNA upregulation was observed in NSCLC tissues (p<0.0001), being more 33 
prominent in squamous carcinomas (p<0.0001). AURKB expression in cell lines strongly 34 
correlated with sensitivity to both docetaxel (p=0.004) and paclitaxel (p=0.007). AURKB 35 
knock-down derivatives consistently showed a dose-dependent association between low 36 
AURKB expression and resistance to paclitaxel. Specific chemical inhibition of Aurora B 37 
activity also demonstrated a strong dose-dependent efficiency in triggering paclitaxel 38 
resistance. 39 
Conclusion  40 
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Aurora B activity is an important modulator of taxane response in NSCLC cells. This may lead 41 




Lung cancer is currently responsible for almost a quarter of cancer-related deaths in the 44 
developed countries. Non-Small Cell Lung Carcinoma (NSCLC) is the most frequent type with 45 
adenocarcinoma (AdC) and Squamous Cell Carcinoma (SqCC) being the most common 46 
sybtypes (Travis et al). Despite the recent advances in targeted therapies for lung cancer, 47 
including agents targeting EGFR, VEGF and ALK, the therapeutic regimes currently used for 48 
NSCLC treatment are largely still based on the use of organometallics and anti-mitotics 49 
(Camidge et al, 2014).  50 
Taxanes are microtubule targeting agents (MTAs), which are used to treat a variety of 51 
human cancers (Del Mastro et al, 2013), (Isonishi et al, 2013), (Van Veldhuizen et al, 2003) 52 
including lung carcinomas (Maemondo et al, 2014). Paclitaxel and Docetaxel represent the 53 
most prominent members of the taxane family and have manifested significant activity, 54 
mainly used as part of complex chemotherapeutic regimens (Tsao et al, 2011), (Oh et al, 55 
2013) or less frequently as monotherapy (Herbst et al, 2010), (Chu et al, 2005). The cytotoxic 56 
action of these compounds is mediated primarily through their binding of β tubulin 57 
monomers, leading to microtubule stabilization, thus blocking their depolymerization and 58 
subsequently triggering cell cycle arrest at the G2/M phase (Monzo et al, 1999). However, 59 
many other pathways may also be involved in modulating their therapeutic effect. Thus far, 60 
the range of relevant interactions is not clear and the mechanisms related to taxane 61 
resistance acquisition are largely unexplored, in spite of their long clinical use in cancer 62 
therapeutics (Murray et al, 2012), (Che et al, 2013). Although an increasing number of 63 
targeted therapeutic agents have come into clinical use (Kris et al, 2014), it is estimated that 64 
taxanes will still be used in chemotherapy regimens for lung cancer treatment for the 65 
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foreseeable future (Cagle & Chirieac, 2012). Therefore, the identification of relevant 66 
response predictors will highly benefit clinical practice by stratifying patients into suitable 67 
currently available schemes (Cottini & Lautenschlaeger, 2013). 68 
A number of genes have been previously implicated in taxane resistance in NSCLC. 69 
Functional p53 was shown to induce sensitivity to docetaxel (Jinturkar et al, 2012) and 70 
paclitaxel (Guntur et al, 2010) in NSCLC cell lines. A phase-III randomized trial showed that 71 
KRAS mutations decrease response of NSCLC to therapy involving paclitaxel, carboplatin and 72 
erlotinib (Eberhard et al, 2005). It is reasonable to hypothesize that the expression of genes 73 
involved in mitotic spindle formation may be predictors of sensitivity to taxanes. Tubulin βIII 74 
mutations have been associated with resistance to taxanes in NSCLC patients (Kaira et al, 75 
2013) as well as cultured lung cancer cells (Kavallaris et al, 1999). However, the inclusion of 76 
TUBB3 expression levels in the prediction model for docetaxel sensitivity shows no 77 
improvement while certain drug pump genes (MRP5 and MVP) and detoxification genes 78 
appear as better predictors (Glaysher, Yiannakis et al. 2009). The CHFR gene has also been 79 
suggested as a potential predictor of response of NSCLC patients to first-line therapy with 80 
carboplatin and paclitaxel (Pillai et al, 2013). Nevertheless, the available information on 81 
taxane efficacy predictors does not provide conclusive evidence. Considering the role of 82 
Aurora kinases in spindle formation and the reported extent of their deregulation in cancer, 83 
one may hypothesize that Aurora-dependent modulation of taxane efficiency is probable.  84 
Aurora kinase B (AURKB) is a member of the Aurora kinase subfamily of conserved 85 
Serine/Threonine kinases, which also includes Aurora A and Aurora C. Deregulation of 86 
Aurora kinases leads to impairment of mitotic spindle checkpoints causing abnormal spindle 87 
assembly (Fu et al, 2007). Aurora B is encoded by the AURKB gene (17p13.1) and plays a key 88 
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role during mitosis by regulating chromosomal alignment, segregation and cytokinesis, as 89 
the catalytic protein of the Chromosomal Passenger Complex (CPC). Activation of Aurora B 90 
by INCENP is required for promoting transfer of the CPC sub-complex (INCENP–Survivin–91 
Borealin subcomplex) to the spindle midzone during mitotic exit (Xu et al, 2009). Here, it is 92 
localized to the centromere and is required for kinetochore localization and chromosome 93 
attachment to the mitotic spindle (Hauf et al, 2003), as well as establishing the spindle 94 
assembly checkpoint (SAC) to correct anomalous chromosome-kinetochore microtubule 95 
attachment before the cell enters anaphase (Carmena et al, 2012). 96 
AURKB is frequently overexpressed in NSCLC (Vischioni et al, 2006) and is associated with 97 
genetic instability (Smith et al, 2005), aneuploidy and poor patient prognosis (Takeshita et al, 98 
2013). However, high Aurora B kinase expression has been associated with improved 99 
relapse-free survival (RFS) in ovarian cancer patients on taxane-based therapy (Beussel et al, 100 
2012). Currently, there is very limited information on the potential impact of Aurora B on 101 
taxane response in cancer cells. In this study, we confirmed the extent of AURKB 102 
deregulation in NSCLC and utilized in vitro approaches to investigate the hypothesis that 103 
AURKB activity may modulate and thus be predictive of the sensitivity to taxanes in NSCLC.   104 
METHODS 105 
Primary NSCLC tumour samples:  This study was undertaken in association with the 106 
Liverpool Lung Project. Appropriate Ethical approval has been acquired and all patients have 107 
provided written informed consent. 132 snap-frozen  tumour samples were obtained at 108 
surgery and included in the study; 56 from AdC and 76 from SqCC. Pathological review of the 109 
sections used in this study confirmed inclusion of only specimens with >70% tumour cell 110 
content. In addition, 44 non-tumour paired surgical tissues (20 from AdC and 24 from SqCC 111 
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patients) were available for analysis, taken from the distant edge of the lung resection. The 112 
clinicopathological characteristics of this cohort are provided in Supplementary Table 1. The 113 
median age of those patients was 67 (45-82); 56 of the patients were females and 77 were 114 
males. 115 
Cell lines & Growth conditions: All cell lines in this study were authenticated using the 116 
GenePrint® 10 System (Promega) and analysis on a 3130 Genetic Analyzer (Life 117 
Technologies) and mycoplasma tested utilising the e-MycoTM plus Mycoplasma PCR 118 
Detection Kit (Intron Biotechnology). Nine NSCLC cell lines (A549, Calu-3, CALU6, CRL5802, 119 
COR-L23, H358, LUDLU-1, SK-LU-1 & SK-MES1) were cultured  in Dulbecco’s Modified Eagle’s 120 
Medium (DMEM)/Ham’s Nutrient Mixture F-12 (1:1) containing  5% Fetal Bovine Serum 121 
(Sigma-Aldrich). Non tumourigenic immortalised human bronchial epithelial cells (HBEC-3KT) 122 
along with their isogenic derivatives; p53 knockouts (HBEC-3KT-53), KRAS mutants 123 
(HBEC_3KT_R) and cells with both aberrations (HBEC-3KT-R53) were also employed in this 124 
study. HBECs were cultured in Keratinocyte-SFM medium supplemented with 50μg/mL 125 
Bovine Pituitary Extract (BPE) and 5 ng/mL human recombinant Epidermal Growth Factor 126 
(rEGF) (Life Technologies). All cell lines were maintained at 37oC, 5% CO2. 127 
Knock-down of AURKB by short hairpin RNA (shRNA): A549 and SK-MES1 cell lines were 128 
transfected with five different AURKB-targeting MISSION® shRNA constructs (Sigma-Aldrich, 129 
clone numbers: TRCN0000000777, TRCN0000000776, TRCN0000000778, TRCN0000000779 130 
and TRCN0000010547) along with a scrambled control construct, using Attractene 131 
Transfection Reagent (Qiagen). Stable clones were selected by exposure to Puromycin (4 132 
nM) and knockdown efficiency was confirmed by qPCR and western blotting. 133 
AURKB overexpression  134 
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The AURKB-PCMV6-XL4 construct (Cat no. PCMV6XL4, SC117526 NM_004217 AURKB – 135 
OriGene, USA) was digested with PsiI (New England Biolabs, UK) and ligated with a 136 
Blasticidin cassete containing fragment which was derived by SmaI digestion of the 137 
pCMV/Bsd plasmid (Catalogue no. V510-20 - Life Technologies, UK). Standard blunt end 138 
ligation was performed using T4 DNA ligase (New England Biolabs, UK). One Shot TOP10 139 
Chemically Competent E. coli cells (Invitrogen) were transformed and clones were selected 140 
for validation. The derived constructs were confirmed by dideoxyterminator sequencing (Life 141 
Technologies, UK).  142 
CALU3 cell line was transfected with pCMV6-XL4-AURKB/Bsd recombinant plasmid using 143 
Attractene Transfection Reagent (Qiagen). Stable transfectant clones were selected in the 144 
presence of 5 µg/ml Blasticidin (SIGMA, UK). mRNA overexpression of AURKB was confirmed 145 
by qPCR. 146 
Taxane and AZD1152 (Barasertib) exposure experiments. Depending on the growth rate of 147 
each cell line, 5 × 104 to 8 × 104 cells were seeded in each well of flat-bottomed 48-well 148 
plates in 6 replicates and cultured in 500 μl of medium. After overnight incubation, the 149 
medium was replaced with media containing a range of Paclitaxel (Sigma-Aldrich) or 150 
Docetaxel (FLUKA) concentrations (0-35nM) and/or Barasertib (Selleck Chemicals) (0-3.2 151 
nM). Cells were incubated for 72 hours with replenishment of medium with drug at 36 152 
hours. Toxicity was measured by MTT assay. Briefly, 200 μL of fresh medium containing 0.75 153 
mg/ml 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (Sigma-Aldrich) was 154 
added and incubated at 37⁰C for three hours. Cells were lysed using 0.04M HCl in 155 
isopropanol and the optical density (O.D.) was measured at 590nm with 630nm as reference 156 
in a GENios plate reader (Tecan Austria GmBH).  157 
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DNA and RNA extraction, Reverse Transcription and qPCR: DNA was extracted from cell 158 
lines and primary lung tumours using the DNeasy® Blood and Tissue Kit (QIAGEN). Total RNA 159 
was extracted using Direct-zol™ RNA MiniPrep Kit (Zymo Research). Quality and quantity of 160 
DNA and RNA were determined using a NanoDrop 2000 Spectrophotometer (Thermo 161 
Scientific). 200ng RNA was Reverse Transcribed using the High Capacity cDNA Reverse 162 
Transcription Kit (Life Technologies). A predesigned FAM labelled Taqman expression assay 163 
(Hs00945858_g1 - Life Technologies) was employed to analyse AURKB  mRNA expression, 164 
with a VIC-labelled ACTB Taqman assay (4326315E – Life Technologies) serving as 165 
endogenous control. Real-time PCR assays were performed in triplicate using a 166 
StepOnePlus™ Real-Time PCR System (Life Technologies).  HBEC-3KT RNA was used as 167 
calibrator for calculating delta delta cycle thresholds (ΔΔCt) and relative quantification (RQ) 168 
values. 169 
Western blotting: Cultured cells were lysed in SDS-based cell lysis buffer containing 170 
protease/phosphatase inhibitors and whole cell lysates were sonicated 10 times for 5-15 sec 171 
with 10 sec intervening pauses [AC 100V 50/60 HZ]. Protein concentrations were determined 172 
using the BCA assay (Thermo Scientific) on a NanoDrop 2000 Spectrophotometer (Thermo 173 
Scientific). Ten to fifty μg of total protein was reduced by NuPAGE Reducing Agent (Life 174 
Technologies) and incubated at 70°C for 10 minutes. Samples were run in NuPAGE Novex 175 
Bis-Tris Gels utilising NuPAGE Antioxidant containing NuPAGE MES Running Buffer (Life 176 
Technologies).  Electroblotting on PVDF membranes was undertaken by iBlot Dry Blotting 177 
System (Life Technologies). The iBind Western System (Life Technologies) was employed for 178 
application of blocking, primary and secondary antibodies (at dilution 1:1000) and washing 179 
steps. Mouse monoclonal primary antibodies to total Histone H3 (phospho S10) (ab14955) 180 
and β-actin (ab8226) (Abcam) were used, while IRDye 800CW Goat Anti-Mouse (LI 925-181 
10 
 
32210) antibody (Odyssey®- LI-COR Biosciences) served as secondary. The immune 182 
complexes were detected using Odyssey® CLx Infrared Imaging System (Odyssey®- LI-COR 183 
Biosciences). 184 
Statistical analysis:   185 
All Statistical analyses were performed using IBM® SPSS® statistical software version 22.0 186 
(Armonk, NY: IBM Corp) unless otherwise stated. Covariates were assessed for compliance 187 
to normal distribution graphically using histograms and by analytical methods using 188 
Kolmogorov-Smirnov/Shapiro-Wilk tests. In the absence of normality, Mann-Whitney, 189 
Wilcoxon rank or Kruskal-Wallis was employed to assess the difference in AURKB mRNA 190 
expression and response to taxanes. Kaplan-Meier method was employed for survival 191 
analysis and statistical differences between groups were examined with Log-rank test. The 192 
IC50 values were calculated using Prism 5 (GraphPad) in comparison to untreated cells at 193 
time 0.   194 
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RESULTS  195 
AURKB mRNA is overexpressed in NSCLC tissues and cell lines. 196 
mRNA expression profiling of AURKB in  snap-frozen tissues demonstrated significant 197 
overexpression of the gene transcript in tumour tissue compared to the adjacent normal 198 
tissues (Mann-Whitney test, p<0.0001, Figure 1A). This overexpression was more profound 199 
in SqCC than AdCs (Mann-Whitney test, p<0.0001, Figure 1B).  In addition, AURKB expression 200 
was more elevated in higher pathological T stages (T1 vs T2, p=0.012, Supplementary figure 201 
1), however, this finding has to be treated with caution as the great majority of tumours in 202 
this sample set fall into the pT2 stage group (n=101)  while pT1 and pT3/4 group comprised 203 
19 and 12 patients respectively. This bias reflects the stage distribution among the operable 204 
NSCLC cases in the UK and therefore our access to the relevant tissue. AURKB upregulation 205 
did not demonstrate a significant impact on overall survival (OS) in this set, although a non-206 
significant trend was demonstrated in adenocarcinoma patients (p=0.079, Supplementary 207 
Figure 2). Survival analysis using the top and bottom terciles instead of the median did not 208 
result in a significant relationship, most probably due to the significant reduction of numbers 209 
of patients in these groups. This weak correlation prompted us to check the available data in 210 
the public domain. In there (http://kmplot.com/analysis/index.php?p=service&cancer=lung) 211 
when selecting all NSCLC, AURKB expression significantly reduces survival (p<10-16). However 212 
when selecting only the NSCLC group subjected to chemotherapy this correlation is not true 213 
(p=0.3). No further associations were found between AURKB mRNA expression and age, 214 
gender, clinical stage or nodal status in our patient set.  215 
AURKB mRNA expression profiling was also undertaken in a panel of lung cancer cell lines, 216 
along with immortalized normal human bronchial epithelial cells (HBEC-3KT and its isogenic 217 
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p53 knockout and KRAS mutant derivatives). AURKB expression was variable among the lung 218 
cancer cell lines, however, it was markedly higher in comparison to that of non-tumourigenic 219 
HBECs (Figure 2). It is of note that among HBECs AURKB mRNA expression was higher in the 220 
p53 knockout derivatives (HBEC3KTp53 and HBEC3KTRp53) while a borderline reduction was 221 
seen in KRAS mutants (HBEC3KTR). 222 
Modulation of NSCLC cells resistance to taxanes by AURKB expression. 223 
The IC50 values for paclitaxel and docetaxel toxicity among the available lung cell lines were 224 
determined following treatment with a range of concentrations (1 - 35 nM) of the two drugs 225 
(Supplementary table 2). IC50s for docetaxel were consistently lower than those of paclitaxel 226 
with one exception (SKLU1 cells). Interestingly, mRNA expression of AURKB in NSCLC cell 227 
lines inversely correlated with resistance to both docetaxel (Spearman’s test, rho=-0.850, 228 
p=0.004) and paclitaxel (rho= -0.817, p=0.007, Supplementary table 2). We explored the 229 
hypothesis this effect simply being a correlation between taxane resistance and doubling 230 
time (Supplementary table 3). However, our results did not demonstrate any correlation 231 
between doubling time with either AURKB expression (Spearman’s test, rho=-533, p=0.139) 232 
or resistance to paclitaxel (rho=0.333, p=0.381) or docetaxel (rho=0.500, p=0.170, 233 
Supplementary table 2). 234 
In order to further explore the possible modulation of taxane response by AURKB, we 235 
investigated the resistance of lung cancer cell lines to paclitaxel by (a) knocking down AURKB 236 
expression and (b) chemically inhibiting its activity. Successful AURKB knock down clones 237 
were derived from A549 and SK-MES1 cells using different shRNA constructs. Knock-down 238 
efficiency was assessed by qPCR and western blot (Figure 3). The clones, as expected, 239 
demonstrated variable knock down efficiency. When exposing these clones to paclitaxel it 240 
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was apparent that response to the drug inversely correlated to the level of AURKB mRNA 241 
expression in a dose-dependent manner. This was true for both clones derived from A549 242 
and 4 clones derived from SK-MES1, while scrambled shRNA clones did not demonstrate 243 
altered response to paclitaxel when compared to the paternal cells (Figure 3).  244 
Additional support to the knock down experiments came from overexpressing AURKB in 245 
Calu-3 cell line. A stable overexpressing clone derived from these cells demonstrated higher 246 
sensitivity to paclitaxel (Supplementary figure 6). 247 
Selective inhibition of AURKB desensitizes NSCLC cells to paclitaxel. 248 
In order to gain additional supporting evidence, we undertook selective inhibition of Aurora 249 
B using a highly specific Aurora B inhibitor (Barasertib). After experimentally determining the 250 
IC50s of Barasertib in A549 SK-MES1 and SKLU1 as 0.9 nM 1.2 nM and 2.3 nM respectively, 251 
we simultaneously exposed cells to paclitaxel and a range of Barasertib concentrations. 252 
AURKB inhibition was confirmed by measuring phosphorylation of histone 3 serine 10 253 
(H3S10), which is on one of its prime substrates (Supplementary Figure 3). In addition, we 254 
confirmed that Barasertib exposure does not alter the mRNA expression of AURKB 255 
(Supplementary Figure 3). Barasertib-mediated AURKB inhibition clearly demonstrated a 256 
dose-dependent effect on paclitaxel efficiency; increased Barasertib concentrations resulted 257 
in increased resistance to paclitaxel in all three cell lines (Figure 4). We subsequently 258 
confirmed the Barasertib-mediated resistance to paclitaxel in the remaining NSCLC cell lines 259 
included in this study (LUDLU1, CRL5807, CRL5802, CORL23, CALU6 and CALU3) as well as all 260 
the AURKB knock-down derivatives from SKMES and A549 (supplementary Figure 4). It is of 261 
note that in the AURKB knockdown clones the Barasertib effect, while still visible, is reduced 262 
in comparison to the non-AURKB engineered NSCLC cell lines, as expected. 263 
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DISCUSSION  264 
Aurora B kinase is an important contributor to the mitotic spindle assembly and its 265 
overexpression in human cancer has been frequently reported (Sorrentino et al, 2005), (Lin 266 
et al, 2010) (Pohl et al, 2011), therefore attracting significant interest in both cancer biology 267 
and therapeutics. In this study, we hypothesized that Aurora B activity may be implicated in 268 
modulating cellular response to taxanes, due to its role in mitotic spindle function, which is 269 
the target of these compounds. mRNA profiling of our NSCLC patient cohort confirmed the 270 
extensive overexpression of this gene, as previously reported (Takeshita et al, 2013), 271 
(Vischioni et al, 2006), (Smith et al, 2005). AURKB overexpression seems to be the main 272 
abnormality related with this gene in NSCLC. The relevant entries in COSMIC database 273 
(http://cancer.sanger.ac.uk/cosmic) report low number of point mutations (5/1985, 0.2%), 274 
copy number variations (4/843, 0.4%) and frequent overexpression (139/1008, 13.8%). In 275 
addition to the frequency difference in histological NSCLC types, AURKB overexpression 276 
appeared to be weakly associated with higher pathological stages. This observation may 277 
indicate that AURKB expression deregulation is a progressive phenomenon; however, one 278 
has to replicate this finding in additional cohorts. Nevertheless, investigation of the data 279 
available in TCGA study (http://www.cbioportal.org/index.do) do not show any  pT stage 280 
related differences in lung adenocarcinoma or tumour dimensions  for squamous lung 281 
carcinomas (pT stage was not available in the query in this histology).  282 
The molecular triggers behind AURKB overexpression in NSCLC are not yet clear. We have 283 
investigated a possible relationship between AURKB and KRAS/ TP53 status in the studied 284 
cancer cell lines, however no such correlation was obtained. This is not surprising, as tumour 285 
cell lines are highly abnormal and diverse at the genetic and epigenetic levels, therefore 286 
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many confounding factors will influence AURKB expression. An interesting observation came 287 
from our HBEC isogenic lines (Figure 2), where the addition of mutant KRAS actually 288 
significantly reduces AURKB expression, either in the presence or absence of TP53. This is in 289 
contrast to a single report available (Dos Santos et al, 2016) which demonstrates 290 
upregulation of AURKB by KRAS in a different immortalised lung epithelial cell line. Therefore 291 
it is not yet clear whether KRAS has a positive or negative impact on AURKB expression. In 292 
contrast, TP53 knock-down is clearly associated with increased AURKB levels. While no 293 
evidence for direct transcriptional inhibition of AURKB by p53 exists, a possible mechanism is 294 
through c-myc. p53 represses, through induction of miR-145 c-myc (Sachdeva et al, 2009), 295 
which is known to induce expression of both AURKA and AURKB (den Hollander et al, 2010). 296 
AURKB mRNA overexpression alone did not correlate with overall survival, in agreement 297 
with two previous studies (Smith et al, 2005) (Perumal, Singh et al. 2012), although the latter 298 
has suggested that AURKB expression can be part of a prognostic multi-gene signature. In 299 
contrast, immunohistochemical analysis of AURKB protein expression was reported to 300 
correlate with poor prognosis (Takeshita et al, 2013; Vischioni et al, 2006) suggesting that 301 
stability and/or correct localization of the protein may also be important.  302 
AURKB mRNA expression was higher in all lung cancer cell lines tested in comparison to 303 
HBECs, as has been previously described (Hayama et al, 2007). The most significant 304 
observation of this study is the inverse correlation found in NSCLC cell lines between AURKB 305 
mRNA expression and sensitivity to both tested taxanes, with low levels of AURKB being 306 
associated with taxane resistance. The hypothesis that this change in resistance might be 307 
simply the reflection of a reduction in doubling times was disproved, as no such correlation 308 
was demonstrated. In order to verify the inverse correlation found between the endogenous 309 
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AURKB levels and taxane resistance, we knocked down AURKB mRNA expression in two lung 310 
cancer cell lines. This knockdown consistently triggered a marked increased resistance to 311 
paclitaxel. Moreover, it was observed that different knock down efficiency in each clone led 312 
to a different level of resistance to paclitaxel, showing for the first time a quantitative effect 313 
between expression of this gene and modulation of resistance to a taxane in human cancer 314 
cells. 315 
In order to exclude possible off-target effects of genetic manipulation, we used a highly 316 
selective AURKB inhibitor (Barasertib or AZD1152), which was reported to have a 3700-fold 317 
higher specificity for AURKB inhibition in comparison to AURKA (Walsby et al, 2008; Yang et 318 
al). This experiment also demonstrated a clear dose-dependent increase of resistance to 319 
paclitaxel with increasing concentrations of Barasertib in all cell lines tested. Barasertib 320 
effect, as hypothesized, was moderated when tested in AURKB knockdown clones, due to 321 
the already reduced availability of AURKB protein in these clones. This data is in contrast to a 322 
previous report suggesting that Aurora B inhibition sensitizes cells to antimitotic agents 323 
(Tanaka et al). However, that study utilized a generic kinase inhibitor AT9283, which inhibits 324 
Aurora A and other kinases, such as Jak2, Jak3 and Abl kinase as well as Aurora B (Curry et 325 
al). It is well known that Aurora A inhibition enhances chemosensitivity to paclitaxel in 326 
pancreatic cancer cells (Lin et al), to docetaxel in human oesophageal squamous cell 327 
carcinoma (Isham et al) and ovarian cancer cells (Scharer et al), therefore this sensitization 328 
can be most probably attributed to AURKA inhibition. The association of high Aurora B 329 
kinase expression sensitivity to taxane-based therapy has been also shown for ovarian 330 
cancer (Beussel et al, 2012). In addition, miRNA-dependent knock-down of AURKB also 331 
results in resistanse to taxanes in an in vivo breast cancer model (Winsel et al, 2014) . 332 
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Therefore the mechanism behind resistance to pacitaxel therapy due to AURKB mitotic 333 
checkpoint abrogation is not limited to NSCLC and appears to be getting well established. 334 
Possible mechanisms to explain the effect of Aurora B on taxane efficiency may be drawn 335 
from a number of previous observations. Paclitaxel acts by perturbation of mitotic spindle 336 
assembly and activating the spindle assembly checkpoint (SAC) (Zachos et al), (Hung et al). 337 
This leads to a cell death response triggered through p53-independent apoptotic pathways 338 
that depend upon maintaining mitotic arrest (Huang et al). If mitotic slippage occurs, evasion 339 
of apoptosis is allowed, mainly due to the stabilization of anti-apoptotic proteins (Wertz et 340 
al). The use of Aurora B inhibitors (Hauf et al, 2003), (Ditchfield, 2003), (Vader et al), (Girdler 341 
et al), deactivation of Aurora B (Wang et al) or depletion of Aurora B activating proteins 342 
(Petsalaki et al), (Vader et al) have shown to relieve mitotic arrest caused by paclitaxel. 343 
Taken together, these studies provide further evidence for the central role of Aurora B 344 
function for spindle checkpoint activation and cell death in response to low-dose paclitaxel 345 
and further support our findings. 346 
Concerning the evidence so far, AURKB expression presents with a potential paradox: Its 347 
overexpression reduces survival in the chemotherapy naïve patients but appears to have a 348 
beneficial effect in patients treated with taxane regimens. The latter may draw additional 349 
support from the loss of the very strong correlation between AURKB and NSCLC patient 350 
survival available online and mentioned in the results section, when limiting the question in 351 
the chemotherapy recipient group. Of course “chemotherapy” term in there is inclusive of 352 
every scheme used but nevertheless raises the question for investigating AURKB 353 
involvement in the resistance modulation of other common chemotherapeutics. 354 
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The present study clearly demonstrated a role for Aurora B in the response of NSCLC cells to 355 
paclitaxel and provided unique evidence for a dose-dependent association. Given the large 356 
extent of AURKB deregulation in NSCLC, these findings suggest that assessing the levels of 357 
AURKB protein in surgical samples and/or biopsy material could assist in the clinical decision 358 
tree for managing patients with NSCLC and have potential for development as a predictive 359 
biomarker. Unfortunately, chemotherapy data were not available for our tissue cohort, thus 360 
we could not investigate any correlation between AURKB expression and response to 361 
taxanes in this clinical set. Our findings, however, highlight the need for conducting such 362 
studies in large cohorts of NSCLC patients.   Moreover, it may advise against the use of 363 
AURKB inhibitors in regimens involving taxanes and this should be further investigated in 364 
clinical studies.   365 
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Figure Legends 370 
Figure 1. Boxplots demonstrating AURKB mRNA expression in primary lung tumours 371 
compared to adjacent normal lung tissues (A) and  in squamous cell carcinomas (SqCC) 372 
compared to adenocarcinomas (AdC) (B). P values are derived from Mann-Whitney tests. 373 
RQ was calculated using RNA from the non-tumourigenic cell line HBEC3KT as a 374 
calibrator. Larger circles represent outlier values (>1.5 x interquartile range); smaller 375 
circles represent extreme values (>3 x interquartile range). 376 
Figure 2. AURKB mRNA expression in human bronchial epithelial cells (HBEC) and lung 377 
cancer cell lines. Bars represent mean values from 6 biological repeats and error bars 378 
represent standard error of the mean. All NSCLC cell lines show a higher expression than 379 
the non-tumourigenic immortalized bronchial cells (HBEC3KT). Also, an increased AURKB 380 
expression is shown in the isogenic p53 derivatives (3KT-53 and 3KT-R53) of the latter. 381 
Figure 3. Paclitaxel response of lung cancer cell lines A549 and SK-MES1 and their AURKB 382 
knock down derivative clones in relation to AURKB mRNA and protein expression. Error 383 
bars in both the line graphs and the expression bar charts represent 95%CI. –PAR: 384 
parental, -SCR: scrambled, -Bx-y: knockdown clones where x is the shRNA construct and y 385 
is the clone number from this transfection. It is of note that the different knockdown 386 
efficiencies in the clones are associated with inverse impact on paclitaxel sensitivity. 387 
Figure 4. Sensitivity of lung cancer cell lines to paclitaxel in the presence of the highly 388 
selective Aurora B inhibitor (Barasertib). Error bars represent 95%CI. A clear quantitative 389 
effect is demonstrated where increasing concentrations of Barasertib, and therefore 390 
inhibition of AURKB activity, is associated with increased resistance to paclitaxel. 391 
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